Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Low-Dose Aspirin Safety, CVD Efficacy “Superior” To Higher Doses – McNeil

This article was originally published in The Tan Sheet

Executive Summary

Low-dose aspirin in the range of 81 mg-162 mg has a superior bleeding profile and similar efficacy to higher OTC doses for cardiovascular protection, Eric Topol, MD, Cleveland Clinic Foundation, told the FDA's Nonprescription Drugs Advisory Committee

You may also be interested in...



Aspirin 68% Mortality Reduction In Coronary Bypass Patients Seen In Study

Aspirin was associated with a 44%-70% reduction in major adverse events when taken within 48 hours of coronary-artery bypass surgery, according to a study in the Oct. 24 New England Journal of Medicine

Aspirin 68% Mortality Reduction In Coronary Bypass Patients Seen In Study

Aspirin was associated with a 44%-70% reduction in major adverse events when taken within 48 hours of coronary-artery bypass surgery, according to a study in the Oct. 24 New England Journal of Medicine

Aspirin 68% Mortality Reduction In Coronary Bypass Patients Seen In Study

Aspirin was associated with a 44%-70% reduction in major adverse events when taken within 48 hours of coronary-artery bypass surgery, according to a study in the Oct. 24 New England Journal of Medicine

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel